ROS-Mediated Nano Drug Delivery for Antitumor Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 1352
Special Issue Editors
Interests: antitumor nanomedicine; ROS-mediated tumor oxidation therapy; ROS-responsive prodrug/nanodrug delivery; ROS-mediated immunotherapy; ROS-mediated combination therapy; advanced targeted drug delivery system with nanomedicine or macrophage; ROS-responsive hydrogel
Special Issue Information
Dear Colleagues,
We are pleased to invite you to submit original research papers and reviews in the field of ROS-mediated antitumor nanomedicine. ROS are a class of chemically reactive small molecules containing oxygen. Compared with normal cells, tumor cells generally have higher concentrations of ROS and are more susceptible to oxidative stress-induced cell death, which makes ROS-based therapies inherently tumor-selective. ROS-mediated tumor oxidation therapy and ROS-responsive drug delivery system are two key components of ROS-mediated therapies. Recently, ROS has emerged as an innovative and unique treatment mode as it can not only directly kill tumor cells but also induce immunogenic cell death (ICD) to activate the body’s immune responses. In addition, it can be easily generated and modulated by means of photodynamic therapy (PDT), sonodynamic therapy (SDT), chemodynamic therapy (CDT), radiodynamic therapy (RDT), microdynamic therapy (MDT), and electrodynamic therapy (EDT).
This Special Issue aims at gathering recent advancements in this field, encompassing topics such as PDT, SDT, CDT, RDT, MDT, EDT, ROS-mediated immunotherapy, ROS-responsive drug delivery system for anti-tumor nanomedicine, and other related topics.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: ROS-mediated tumor oxidation therapy/combination therapy, ROS-responsive anti-tumor drug delivery system, ROS-mediated tumor immunotherapy, and other related areas.
We look forward to receiving your contributions.
Dr. Yanjuan Huang
Dr. Xiaoyu Xu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antitumor therapy
- reactive oxygen species (ROS)
- ROS-mediated biomedical nanotechnology
- ROS-responsive nano drug delivery
- ROS-mediated immunotherapy
- ROS-mediated combination therapy
- oxidation therapy
- photodynamic therapy (PDT)
- sonodynamic therapy (SDT)
- chemodynamic therapy (CDT)
- radiodynamic therapy (RDT)
- microdynamic therapy (MDT)
- electrodynamic therapy (EDT)
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
